0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkB

TrkB

TrkB Molecule Information

Name:Neurotrophic tyrosine kinase receptor type 2
Target Synonym:GP145-TrkB;BDNF/NT-3 growth factors receptor;Neurotrophic tyrosine kinase receptor type 2;Tropomyosin-related kinase B;Trk-B;TRKB;TrkB tyrosine kinase;NTRK2
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

TrkB Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
NT2-H5228 Human Human TrkB / NTRK2 Protein, His Tag
NT2-H5228-structure
NT2-H5228-sds
NT2-H5254 Human Human TrkB / NTRK2 Protein, Fc Tag
NT2-H5254-structure
NT2-H5254-sds

TrkB Molecule Synonym Name

NTRK2,TRKB,GP145-TrkB

TrkB Molecule Background

Neurotrophic tyrosine kinase receptor type 2 (NTRK2) is also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is ¡°ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate¡±. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

TrkB References

TrkB Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Entrectinib NMS-E628; RG-6268; RXDX-101 Approved Nerviano Medical Sciences, Ignyta Pharma, Chugai, Genentech Entrectinib 日本 Solid tumours 中外制药 2019-06-18 00:00:00.0 Solid tumours Details
Cabozantinib S-malate XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 Approved Exelixis, Ipsen, Takeda COMETRIQ fda Medullary thyroid cancer (MTC) EXELIXIS 2012-11-29 Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) Details
Larotrectinib sulfate ARRY-470; LOXO-101 Approved Array BioPharma, Loxo Oncology, Bayer VITRAKVI fda Solid tumours BAYER HLTHCARE 2018-11-26 Solid tumours Details

TrkB Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Repotrectinib TPX-0005,TPX0005,TPX 0005 Phase Ⅱ Turning Point Therapeutics Non small cell lung cancer (NSCLC), Solid tumours Details
Brain-derived neurotrophic factor Phase Ⅱ Max Planck Institute of Experimental Medicine, Sumitomo Dainippon, Amgen, Regeneron Pharmaceutical Amyotrophic lateral sclerosis (ALS) Details
BN-201 BN-201 Phase Ⅰ Bionure Optic neuritis, Neuromyelitis optica (NMO) Details
Altiratinib DCC-22701; DCC-2701; DP-5164; T-678746713 Phase Ⅰ Deciphera Solid tumours Details
CE-245677 CE-245677 Phase Ⅰ Pfizer Cancer Details
DS-6051 DS-6051; DS-6051a; DS-6051b,DS6051,DS6051a,DS6051b Phase Ⅰ Daiichi Sankyo, AnHeart Therapeutics Solid tumours Details
Lestaurtinib A-154475.0; CEP-701; KT-5555; SP-924; SPM-924 Phase Ⅲ Kyowa Hakko Kirin, Cephalon Acute lymphoblastic leukaemia (ALL) Details
PLX-7486 PLX-7486; PLX7486-TsOH Phase Ⅱ Daiichi Sankyo Solid tumours, Pancreatic cancer Details
ACD-855 ACD-855 Phase Ⅰ AlzeCure Pharma AB Alzheimer's disease (AD) Details

This web search service is supported by Google Inc.

totop